论文部分内容阅读
目的研究恶性淋巴瘤(ML)中血清癌抗原125(CA125)水平变化,并探讨其临床意义。方法收集广州市南沙中心医院和广州市第一人民医院血液内科确诊116例ML患者,以同期入院的慢性再生障碍性贫血患者为对照,检测ML血清CA125水平,分析血清CA125水平与临床特征、分期、β2-MG、LDH、治疗反应、组织类型及预后等关系。结果116例ML患者,血清CA125水平升高有54例,占46.6%,ML初治组患者血清CA125水平较对照组、治疗后部分缓解(Partial remission,PR)或完全缓解组(Complete remission,CR)升高,差异有统计学意义(P<0.05),CR组较对照组差异无统计学意义,而复发或进展组(Progressive disease,PD)血清CA125水平较CR组再次升高。ML初治时血清CA125水平与β2-MG、LDH、分期、渗出、B症状、结外病变数目、IPI有明显相关性,血清CA125水平正常组较升高组CR率明显升高(P<0.05)。结论血清CA125水平可反映ML的侵袭性、治疗反应,对ML的分期、预后具有重要临床价值;血清CA125水平可能在HL中有一定临床价值。
Objective To study the changes of serum CA125 levels in patients with malignant lymphoma (ML) and to explore its clinical significance. Methods A total of 116 patients with ML diagnosed by Department of Hematology, Guangzhou Nansha Central Hospital and Guangzhou First People’s Hospital were enrolled in this study. The serum level of CA125 in ML patients was compared with patients with chronic aplastic anemia admitted in the same period. The serum CA125 levels and clinical features were analyzed. , Β2-MG, LDH, treatment response, tissue type and prognosis. Results The serum level of CA125 in 116 patients with ML was 54 (46.6%). The level of serum CA125 in ML group was significantly higher than that in control group, Partial remission (PR) or Complete remission (CR) ), The difference was statistically significant (P <0.05). There was no significant difference between the CR group and the control group, while the serum CA125 level in the recurrent or progressive group (PD) was higher than that in the CR group. The serum level of CA125 in newly diagnosed ML patients was significantly correlated with β2-MG, LDH, stage, exudation, B symptoms, number of extranodal lesions and IPI. The serum CR125 levels in normal subjects were significantly higher than those in normal subjects (P < 0.05). Conclusions The level of serum CA125 can reflect the aggressiveness of ML, response to treatment, and has important clinical value for the staging and prognosis of ML. The level of serum CA125 may have some clinical value in HL.